{
  "disease_name": "Prostate cancer",
  "synonyms": [
    "Prostatic adenocarcinoma",
    "Cancer of the prostate"
  ],
  "summary": "A malignancy of the prostate gland, most commonly adenocarcinoma, ranging from indolent localized tumors to aggressive metastatic disease; detection is often via PSA screening and confirmed by biopsy with Gleason/Grade Group, and management spans active surveillance to surgery, radiation, androgen deprivation, chemotherapy, targeted and radioligand therapies.",
  "causes": [
    "Accumulation of somatic DNA mutations",
    "Androgen receptor pathway dysregulation",
    "TMPRSS2–ERG gene fusion",
    "Defects in DNA repair pathways"
  ],
  "risk_factors": [
    "Older age",
    "Family history (first-degree relative)",
    "African ancestry",
    "BRCA2 pathogenic variant",
    "HOXB13 variant",
    "Obesity"
  ],
  "symptoms": [
    "Weak urine stream",
    "Urinary frequency (nocturia)",
    "Dysuria",
    "Hematuria",
    "Hematospermia",
    "Erectile dysfunction",
    "Back or bone pain",
    "Unintentional weight loss",
    "Fatigue"
  ],
  "diagnosis": [
    "PSA blood test",
    "Digital rectal exam (DRE)",
    "Multiparametric MRI",
    "Transrectal/transperineal needle biopsy",
    "Gleason score / Grade Group",
    "AJCC TNM staging",
    "PSMA PET-CT (metastasis assessment)",
    "Bone scan (osteoblastic mets)"
  ],
  "treatments": [
    "Active surveillance",
    "Radical prostatectomy (open/laparoscopic/robot-assisted)",
    "External beam radiation therapy (IMRT)",
    "Brachytherapy",
    "Androgen deprivation therapy (GnRH agonist/antagonist)",
    "Antiandrogens (enzalutamide, apalutamide, darolutamide)",
    "Abiraterone acetate",
    "Docetaxel chemotherapy",
    "Cabazitaxel",
    "Sipuleucel-T",
    "PARP inhibitors (olaparib, rucaparib)",
    "Lu-177 PSMA radioligand therapy",
    "Radium-223 (bone mets palliation)",
    "Zoledronic acid / Denosumab (skeletal events)"
  ],
  "related_genes": [
    "BRCA2",
    "BRCA1",
    "HOXB13",
    "TMPRSS2–ERG",
    "SPOP",
    "FOXA1",
    "PTEN",
    "TP53",
    "RB1",
    "ATM"
  ],
  "subtypes": [
    {
      "name": "Localized low-risk",
      "typical_patients": "PSA <10 ng/mL, Grade Group 1, T1–T2a",
      "five_year_survival": ">95%",
      "common_treatments": [
        "Active surveillance",
        "Radical prostatectomy",
        "Radiation therapy"
      ]
    },
    {
      "name": "Localized intermediate/high-risk",
      "typical_patients": "Higher PSA or Grade Group ≥2, or T2b–T3",
      "five_year_survival": "≈85–95% (stage-dependent)",
      "common_treatments": [
        "Radiation + ADT",
        "Radical prostatectomy ± adjuvant therapy"
      ]
    },
    {
      "name": "Metastatic hormone-sensitive",
      "typical_patients": "De novo or recurrent metastatic disease",
      "five_year_survival": "≈60–80%",
      "common_treatments": [
        "ADT + docetaxel",
        "ADT + AR-targeted agents"
      ]
    },
    {
      "name": "Castration-resistant (mCRPC)",
      "typical_patients": "Progression despite castrate testosterone",
      "five_year_survival": "≈30–40%",
      "common_treatments": [
        "AR-targeted agents",
        "Docetaxel/Cabazitaxel",
        "PARP inhibitor (HRR-mutated)",
        "Lu-177 PSMA",
        "Radium-223 (bone-predominant)"
      ]
    }
  ],
  "epidemiology": {
    "global_cases_2015": "1200000",
    "global_deaths_2015": "350000",
    "most_common_in": "Older men; highest incidence in regions with high life expectancy (e.g., North America, Europe, Australia)",
    "five_year_survival_rate": "Stage-dependent; localized >95%, distant 30–40%"
  },
  "relationships": [
    {
      "source": "Prostate cancer",
      "relation": "has_symptom",
      "target": "Weak urine stream"
    },
    {
      "source": "Prostate cancer",
      "relation": "has_symptom",
      "target": "Urinary frequency"
    },
    {
      "source": "Prostate cancer",
      "relation": "has_symptom",
      "target": "Hematuria"
    },
    {
      "source": "Prostate cancer",
      "relation": "has_symptom",
      "target": "Back or bone pain"
    },
    {
      "source": "Prostate cancer",
      "relation": "has_risk_factor",
      "target": "Older age"
    },
    {
      "source": "Prostate cancer",
      "relation": "has_risk_factor",
      "target": "Family history"
    },
    {
      "source": "Prostate cancer",
      "relation": "has_risk_factor",
      "target": "African ancestry"
    },
    {
      "source": "Prostate cancer",
      "relation": "associated_gene",
      "target": "BRCA2"
    },
    {
      "source": "Prostate cancer",
      "relation": "associated_gene",
      "target": "HOXB13"
    },
    {
      "source": "Prostate cancer",
      "relation": "associated_gene",
      "target": "TMPRSS2–ERG"
    },
    {
      "source": "Prostate cancer",
      "relation": "diagnosed_by",
      "target": "PSA blood test"
    },
    {
      "source": "Prostate cancer",
      "relation": "diagnosed_by",
      "target": "Prostate biopsy"
    },
    {
      "source": "Prostate cancer",
      "relation": "treated_with",
      "target": "Radical prostatectomy"
    },
    {
      "source": "Prostate cancer",
      "relation": "treated_with",
      "target": "Radiation therapy"
    },
    {
      "source": "Prostate cancer",
      "relation": "treated_with",
      "target": "Androgen deprivation therapy"
    },
    {
      "source": "Prostate cancer",
      "relation": "treated_with",
      "target": "Abiraterone"
    },
    {
      "source": "Prostate cancer",
      "relation": "treated_with",
      "target": "Enzalutamide"
    },
    {
      "source": "Prostate cancer",
      "relation": "treated_with",
      "target": "Docetaxel"
    },
    {
      "source": "Prostate cancer",
      "relation": "treated_with",
      "target": "PARP inhibitors"
    },
    {
      "source": "Prostate cancer",
      "relation": "treated_with",
      "target": "Lu-177 PSMA"
    },
    {
      "source": "Localized low-risk",
      "relation": "subtype_of",
      "target": "Prostate cancer"
    },
    {
      "source": "Localized intermediate/high-risk",
      "relation": "subtype_of",
      "target": "Prostate cancer"
    },
    {
      "source": "Metastatic hormone-sensitive",
      "relation": "subtype_of",
      "target": "Prostate cancer"
    },
    {
      "source": "Castration-resistant (mCRPC)",
      "relation": "subtype_of",
      "target": "Prostate cancer"
    }
  ]
}